Calif. High Court Preserves $415M Verdict Against Actelion

Law360, New York (March 13, 2014, 2:45 PM EDT) -- The California Supreme Court declined to review a $415 million jury verdict against Actelion Ltd. on Wednesday in a suit accusing the Swiss pharmaceutical company of purchasing CoTherix Inc. in order to preserve its monopoly in the hypertension drug market.

In an unanimous order, California's high court declined to take up Actelion's appeal of a $415 million million jury verdict in a suit brought by Japanese pharmaceutical maker Asahi Kasei Pharma Corp.

The verdict includes $30 million in punitive damages against three of Actelion's executives, and...
To view the full article, register now.